Prometheus Biosciences Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Prometheus Biosciences Inc (RXDX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Prometheus Biosciences Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 4M vs 813,382M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+10.6% annualized vs trailing 12 months), vs decelerating (-24.6%) for its tracked peer group.
- Growth: Prometheus Biosciences Inc generated -71.8% revenue growth year over year in Q3 2023, vs 9.0% for its competitors combined.
- Profitability: Its -3,699.2% net margin compares with 11.6% for the peer group.
- Peer revenue share: Prometheus Biosciences Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.03M compares with $1.04M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
RXDX Sales vs. its Competitors, Q3 2023
Prometheus Biosciences Inc reported revenue contraction of 71.80 % year on year in Q3 2023, below its competitors' combined revenue growth of 8.98 %.
With a net margin of -3,699.19 %, Prometheus Biosciences Inc reported lower profitability than its competitors (11.57 %).
Prometheus Biosciences Inc generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
API endpoints for this dataset
Prometheus Biosciences Inc vs. its Competitors, Q3 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Prometheus Biosciences Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Prometheus Biosciences Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Prometheus Biosciences Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (126) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Prometheus Biosciences Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs -71.8% for Prometheus Biosciences Inc. Prometheus Biosciences Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Prometheus Biosciences Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Prometheus Biosciences Inc | - | No | No | No |
| Competitors combined (161) | ||||
| High-Confidence Competitors (131) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
RXDX Stock Performance relative to its Competitors
RXDX Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 3 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 4 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 5 | An2 Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Prometheus Biosciences Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Prometheus Biosciences Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Prometheus Biosciences Inc |
9,488.45 | 4.00 |
 Eli Lilly And Company |
1,279,607.89 | 86,462.00 |
 Johnson and Johnson |
687,517.91 | 99,335.00 |
 Abbvie Inc |
520,773.08 | 66,014.00 |
 Merck and Co Inc |
365,658.80 | 66,569.00 |
 Novartis Ag |
319,173.30 | 56,674.00 |
| SUBTOTAL | 5,174,582.48 | 856,862.88 |
Sign in to see all competitors of Prometheus Biosciences Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Prometheus Biosciences Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Prometheus Biosciences Inc's Competitors Named by the Company
Competitive relationships identified from Prometheus Biosciences Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Novartis International AG | Company report | 85% |
| AstraZeneca plc | Company report | 85% |
| Keros Therapeutics Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Pfizer Inc. | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Bayer AG | Company report | 85% |
| Marker Therapeutics inc | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Petvivo Holdings Inc | Company report | 85% |
| Propanc Biopharma Inc | Company report | 85% |
| Bnb Plus Corp | Company report | 85% |
| Northwest Biotherapeutics Inc | Company report | 85% |
| Tempest Therapeutics Inc | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Puretech Health Plc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Mosaic Immunoengineering Inc | Company report | 85% |
| Maia Biotechnology Inc | Company report | 85% |
| Altimmune inc | Company report | 85% |
| Scynexis Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Beone Medicines Ltd | Company report | 85% |
| Inhibrx Biosciences Inc | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Curanex Pharmaceuticals Inc | Company report | 85% |
| Liminatus Pharma Inc | Company report | 85% |
| Quantum si Incorporated | Company report | 85% |
| Bicara Therapeutics Inc | Company report | 85% |
| Nextcure Inc | Company report | 85% |
| Tenax Therapeutics Inc | Company report | 85% |
| Chemomab Therapeutics Ltd | Company report | 85% |
| Trevi Therapeutics Inc | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Personalis Inc | Company report | 85% |
| Enanta Pharmaceuticals Inc | Company report | 85% |
| Ernexa Therapeutics Inc | Company report | 85% |
| BGNE | Company report | 85% |
| Smartkem Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Abivax Sa | Company report | 85% |
| Agomab Therapeutics Nv | Company report | 85% |
| Palatin Technologies Inc | Company report | 85% |
| Elanco Animal Health Incorporated | Company report | 85% |
| Allarity Therapeutics Inc | Company report | 85% |
| Sunshine Biopharma Inc | Company report | 85% |
| Oragenics Inc | Company report | 85% |
| Terns Pharmaceuticals Inc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Absci Corp | Company report | 85% |
| Vaxcyte Inc | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Qnity Electronics Inc | Company report | 85% |
| Mangoceuticals Inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Nascent Biotech Inc | Company report | 85% |
| Sonnet Biotherapeutics Holdings Inc | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Vaccinex Inc | Company report | 85% |
| Mural Oncology Plc | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Instil Bio Inc | Company report | 85% |
| Boehringer Ingelheim GmbH | Company report | 85% |
| Pelthos Therapeutics Inc | Company report | 85% |
| Dynavax Technologies Corporation | Company report | 85% |
| Invo Fertility Inc | Company report | 85% |
| Actuate Therapeutics Inc | Company report | 85% |
| Dupont De Nemours Inc | Company report | 85% |
| Pyxis Oncology Inc | Company report | 85% |
| NAYA | Company report | 85% |
| Optinose Inc | Company report | 85% |
| INVO | Company report | 85% |
| Cell Source Inc | Company report | 85% |
| Coya Therapeutics Inc | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Nanoviricides inc | Company report | 85% |
| Gossamer Bio Inc | Company report | 85% |
| CHRO | Company report | 85% |
| Invivyd Inc | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Elicio Therapeutics Inc | Company report | 85% |
| Gridai Technologies Corp | Company report | 85% |
| ENTO | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Cidara Therapeutics Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Gri Bio Inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Vaxxinity Inc | Company report | 85% |
| Ayala Pharmaceuticals Inc | Company report | 85% |
| Entegris Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Kronos Bio Inc | Company report | 85% |
| Cytokinetics Incorporated | Company report | 85% |
| Agile Therapeutics Inc | Company report | 85% |
| Centessa Pharmaceuticals Plc | Company report | 85% |
| Arbutus Biopharma Corp | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Biorestorative Therapies Inc | Company report | 85% |
| Immutep Limited | Company report | 85% |
| Seagen Inc | Company report | 85% |
| Novavax inc | Company report | 85% |
| Theriva Biologics inc | Company report | 85% |
| Atreca inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Twist Bioscience Corporation | Company report | 85% |
| Lineage Cell Therapeutics Inc | Company report | 85% |
| Ridgeback Biotherapeutics LP | Company report | 85% |
| Carisma Therapeutics Inc | Company report | 85% |
| Palisade Bio Inc | Company report | 85% |
| Essa Pharma inc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Scholar Rock Holding Corp | Company report | 85% |
| Aim Immunotech Inc | Company report | 85% |
| Cytodyn inc | Company report | 85% |
| Enveric Biosciences Inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Better Therapeutics Inc | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Bio techne Corp | Company report | 85% |
| Achieve Life Sciences Inc | Company report | 85% |
| Urogen Pharma Ltd | Company report | 85% |
| Alector Inc | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Alx Oncology Holdings Inc | Company report | 85% |
| Lumos Pharma Inc | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
| Anavex Life Sciences Corp | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Editas Medicine Inc | Company report | 85% |
| Medicines Co | Company report | 85% |
| Vertex Inc | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Zoetis Inc | Company report | 85% |
| Sanofi | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Fortress Biotech Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Bolt Biotherapeutics Inc | Company report | 85% |
| Humanigen Inc | Company report | 85% |
| Lianbio | Company report | 85% |
| Exelixis Inc | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Bellicum Pharmaceuticals Inc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Myovant Sciences Ltd | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Baxter International Inc | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Lexicon Pharmaceuticals Inc | Company report | 85% |
| Tiziana Life Sciences Ltd | Company report | 85% |
| Phibro Animal Health Corporation | Company report | 85% |
| Affimed N v | Company report | 85% |
| Nektar Therapeutics | Company report | 85% |
| Xencor Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Prometheus Biosciences Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Prometheus Biosciences Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Prometheus Biosciences Inc .
Prometheus Biosciences Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Prometheus Biosciences Inc | 9,488 | 27,937 | -1,052,881 |
| Eli Lilly And Company | 1,279,608 | 1,729,240 | 551,594 |
| Johnson and Johnson | 687,518 | 705,504 | 114,311 |
| Abbvie Inc | 520,773 | 1,158,140 | 181,509 |
| Merck and Co Inc | 365,659 | 887,587 | 42,267 |
| Novartis Ag | 319,173 | 752,973 | 185,566 |
| PEERS TOTAL | 5,165,094 | 1,038,386 | 142,561 |
Sign in to see all peers for Prometheus Biosciences Inc .
Prometheus Biosciences Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
| Pfizer Inc | United States 63.93 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Prometheus Biosciences Inc .
Prometheus Biosciences Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (446 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 37.92 % (avg) | -37.9 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.30 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 10.64 % | 7.51 % (avg) | +3.1 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Prometheus Biosciences Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (446 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.5x | - |
| EV / EBITDA | - | 15.4x | - |
| P/B | 12.2x | 4.2x | +7.9x |
| Return on Equity | -33.50 % | industry aggregate | -46.70 % |
| Return on Invested Capital | -17.32 % | -9.78 % (avg) | -7.54 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Prometheus Biosciences Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2014 | 2015 | 2016 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | 154.60 % | 117.61 % |
| Operating Margin | - | - | - | - | - |
| Return on Invested Capital | -23.76 % | -32.77 % | - | -15.88 % | -21.15 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Prometheus Biosciences Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 10.64 % vs industry average 7.51 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Prometheus Biosciences Inc's dedicated Suppliers and Customers pages, not here.
Prometheus Biosciences Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+10.6% annualized vs trailing 12 months).
Weaknesses
- Return on equity 46.7 points below the industry aggregate.
Opportunities
- A meaningful share of competitors (53.80 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-24.6% annualized).
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: see Methodology: SWOT Analysis.
Prometheus Biosciences Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Prometheus Biosciences Inc | 7.04 | 23.30 | - |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
Sign in to see all peers for Prometheus Biosciences Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Prometheus Biosciences Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Prometheus Biosciences Inc | Q1 2023 | -71.8 % | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| PEERS TOTAL | +9.7 % | +9.6 % |
Sign in to see all peers for Prometheus Biosciences Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Prometheus Biosciences Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Prometheus Biosciences Inc | Q1 2023 | - | - |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
Sign in to see all peers for Prometheus Biosciences Inc .
Prometheus Biosciences Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Prometheus Biosciences Inc | - | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
Sign in to see all peers for Prometheus Biosciences Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Prometheus Biosciences Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Prometheus Biosciences Inc | - | 2,375.08 |
| Eli Lilly And Company | 46.50 | 14.80 |
| Johnson and Johnson | 42.48 | 6.92 |
| Abbvie Inc | 50.58 | 7.89 |
| Merck and Co Inc | 119.39 | 5.49 |
| Novartis Ag | 22.82 | 5.63 |
| PEERS AVERAGE | 44.04 | 6.04 |
Sign in to see all peers for Prometheus Biosciences Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.